654 A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY

April 24 tattoo/piercing 4.5%, medical procedures 6.4%, unknown 18.7%.About 48% of patients with GT3 have comorbidities, mostly IVDU.Of them 21% have psychiatric disorders, 7.9% cardiovascular disease and 6.6% HIV-coinfection.RVR rates in both groups were different (73.9%/63.9%)whereas EVR was 93% in both groups.SVR was achieved in 62.1% LVL and 52.6% HVL patients.Patients with RVR achieved SVR in 68.6% and 56.4% of LVL/HVL patients.Patients were treated for a median of 24.4 weeks; 80% cumulative dose was reached for PEG in 83.6% and for RBV in 85.4%.Discontinuation rates accounted for 14.1% in LVL and 14.8% in HVL patients. Conclusion:Comparing SVR results from this cohort with results from ACCELERATE revealed that GT3 patients overall and especially those with RVR achieve lower SVR rates in daily routine as under study conditions.Since most of new antivirals are predominantly active in GT1, treatment optimization studies with PEG/RBV are urgently needed.Characteristics of patients G-3, LVL G-3, HVL G-3, total Age (mean yrs) 36.5 38.0 37.3 Male (%) 59.7 70.8 65.4 BMI (kg/m 2 ) 24.3 24.6 24.4 Duration of HCV infection (mean yrs) 9.5 10.9 10.2 RVR (%) 73.9 63.9 68.5 SVR after RVR (%) 68.6 56.4 62.5 SVR after non-RVR (%) 47.5 43.0 44.7 SVR (%) total 62.1 52.6 57.